Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...
Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer ...
GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.
A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...
Shares in biopharmaceutical company Arcus Biosciences ($RCUS) collapsed 17% in pre-market trading after it said it was ...
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
This story is part of a series on 10 life-saving medical breakthroughs. Click here to read the rest.
INDIANAPOLIS (WISH) — Cancers in younger adults are surging. Colon cancer, once a midlife disease, is striking earlier than ...
Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback